Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Short term Debt (2017)

Aclaris Therapeutics (ACRS) has 1 years of Short term Debt data on record, last reported at $590000.0 in Q4 2017.

  • For Q4 2017, Short term Debt changed N/A year-over-year to $590000.0; the TTM value through Dec 2017 reached $590000.0, changed N/A, while the annual FY2017 figure was $590000.0, N/A changed from the prior year.
  • Short term Debt reached $590000.0 in Q4 2017 per ACRS's latest filing.
  • Across five years, Short term Debt topped out at $590000.0 in Q4 2017 and bottomed at $590000.0 in Q4 2017.